RE:Where are the big boys ??????????depending on how far current funds can carry them, they may not care about SP on the secondary market for now. Personally, I thought that is poor mgt/ethics if that is the case, but I suppose one can look at it this way:
If phase 1 trial data showed significant efficacy, they would not need to worry about financing or share price. "Successful" immunotherapy would hold that kind of power. So now they have to deliver.
Positive data and not much else could lead to share price gains.
I should add that I am well aware that phase 1 is usually deemed a toxicity study, but don't be fooled. I garantee that mgt and Dr's will be looking for signs of melting tumors.